| Novel approaches for myelodysplastic syndromes: beyond hypomethylating agents. | |
| | |
MedLine Citation:
|
PMID: 20178141 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE OF REVIEW: Several novel therapeutic approaches exist for treatment of patients with myelodysplastic syndrome, with goals to improve quality of life and prolong survival. This review highlights new therapies from the last 18 months. RECENT FINDINGS: Immunosuppressants, erythropoiesis-stimulating agents in combination with granulocyte colony-stimulating factor or all-trans-retinoic-acid have shown improvement in decreasing the need for transfusions and improving quality-of-life and/or survival. Eltrombopag has shown promising results in the treatment of thrombocytopenia. However, determination of an optimal chemotherapeutic approach remains elusive and controversial. DNA methyltransferase inhibitors are well tolerated in outpatient settings, with azacitidine prolonging survival and decreasing time to acute myeloid leukemia progression in patients with high-risk myelodysplastic syndromes. A novel erythroid-specific gene expression profile may predict response to lenalidomide in patients who lack the deletion of 5q31.1. Tools such as the Charlson comorbidity index may help select appropriate patients for allogeneic stem cell transplant. A variety of promising new agents are under investigation. SUMMARY: This review focuses on recent advances in new strategies and targeted therapies for treatment of myelodysplastic syndrome. |
| | |
Authors:
|
Arturo Loaiza-Bonilla; Steven D Gore; Hetty E Carraway |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current opinion in hematology Volume: 17 ISSN: 1531-7048 ISO Abbreviation: Curr. Opin. Hematol. Publication Date: 2010 Mar |
Date Detail:
|
Created Date: 2010-02-22 Completed Date: 2010-04-27 Revised Date: 2011-05-04 |
Medline Journal Info:
|
Nlm Unique ID: 9430802 Medline TA: Curr Opin Hematol Country: United States |
Other Details:
|
Languages: eng Pagination: 104-9 Citation Subset: IM |
Affiliation:
|
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Agents
/
therapeutic use Benzoic Acids / therapeutic use* Enzyme Inhibitors / therapeutic use Humans Hydrazines / therapeutic use* Methyltransferases / antagonists & inhibitors Myelodysplastic Syndromes / drug therapy*, physiopathology Pyrazoles / therapeutic use* Quality of Life Thalidomide / analogs & derivatives*, therapeutic use Treatment Outcome |
| Grant Support | |
ID/Acronym/Agency:
|
L30 CA111124-01/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Benzoic Acids; 0/Enzyme Inhibitors; 0/Hydrazines; 0/Pyrazoles; 0/eltrombopag; 191732-72-6/lenalidomide; 50-35-1/Thalidomide; EC 2.1.1.-/Methyltransferases |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than seroty...
Next Document: Urinary fluoride levels in Jamaican children in 2008, after 21 years of salt fluoridation.